Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams Abstract #2143

Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.
Aim(s): To evaluate the response of IBI308 in treating advanced NENs and to find out the effective population by using several biomarkers.
Materials and methods: We had prospectively enrolled patients pathologically diagnosed as NENs after standard treatment failure to receive IBI308 treatment. Most of patients had received IBI308 200mg q3w. Response was assessed every 9 weeks.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Ru Jia

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1468 Evaluation of ENETS and AJCC Staging Systems for Pancreatic Neuroendocrine Neoplasms: A Multicenter Study in China.
Introduction: Accurate staging system is crucial for p-NENs management. The European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/ American Joint Cancer Committee/ World Health Organization (UICC/AJCC/WHO) advocated their TNM staging system for pancreatic neuroendocrine neoplasms (p-NENs) respectively.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Dr Kaizhou Jin
Authors: Jin K, Zhang Y, Luo G, Sun J, ...
#1290 PD-L1 Expression is Associated with Grade of Neuroendocrine Tumors
Introduction: Neuroendocrine neoplasms are divided into well-differentiated neuroendocrine tumors (WDNETs) and poorly differentiated neuroendocrine carcinomas (PDNECs).The correlation between Gastroenteropancreatic Neuroendocrine Neoplasms (GEPNENs) and immunocheck point molecule-PD-L1 is still unclear now.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Professor Zhongwu Li
Authors: Li Z, Leng J, Wang H, Li S, ...
#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anamika Gulati
Authors: Yao J C, Fazio N, Li D, Pavel M, ...
Keywords: PDR001, immunotherapy, NET
#978 Prognostic Value of Somatostatin Receptor Scintigraphy on High-Grade Neuroendocrine Neoplasms and Impact on the Treatment Decision of Intermediate-Grade Neuroendocrine Neoplasms
Introduction: Somatostatin receptor scintigraphy (SRS) could detect not only somatostatin receptors but also tumor images in patients with neuroendocrine neoplasms (NENs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Jian Ming Xu
Authors: Jia R, Fu Y L, Lin L, Wang Y, ...
#2125 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: 400 Cases of Multicenter Retrospective Analysis
Introduction: Definitions of Type 3 gastric NEN (g-NEN) in ENETS Guidelines 2012 and 2016 are ambiguous and controversial, so Four-type classification has been proposed in China.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Huang-Ying Tan
Authors: Li Y L, Zhang P, Qiu X D, Li X K, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.